# Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease

> **NCT04346862** · PHASE4 · UNKNOWN · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 636 (estimated)

## Conditions studied

- Mild Cognitive Impairment

## Interventions

- **DRUG:** Acetyl-L-carnitine hydrochloride 500mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04346862
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01-26
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 636 (ESTIMATED)
- **Last updated:** 2020-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04346862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04346862, "Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04346862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*